In this study, we aimed to evaluate the potential of eNK cells (HLCN061; developed by HEALIOS K.K.), which are human iPSC-derived NK cells differentiated from clinical-grade iPSCs in which IL-15, CCR2B, CCL19, CD16a, and NKG2D have been introduced, in the treatment of HCC. This evidence concerns the gene KLRK1 and hepatocellular carcinoma.